Nona Biosciences

Day 1 at the Festival of Biologics! What an amazing start to the event! We’re excited to already connect with so many of you at Booth #736. If you haven't dropped by yet, there is still time to do it and learn about how our HCAb technology is shaping the future of biotherapeutic development. ?? And don't forget to join Dr. Jiyong Zhang, Nona’s Chief Business Officer, for an insightful session on the latest advancements in immunotherapy using our HCAb Harbour Mice? platform. ??? When: Tomorrow Oct 16 at 9:35 am You won’t want to miss this exciting talk! Let’s continue making breakthroughs together. #FestivalofBiologics #FOB #FOB2024 #HCAb #antibodies #biotherapeutics #Biotech #fullyhuman #CART #ADC #multispecific #bispecific #immunotherapy #Tcellengager #TCE

The Festival of Biologics is just around the corner, taking place next week from October 15-17 in Basel! We’re thrilled to be a Diamond Sponsor this year, and you can find us at Booth #736. Don’t miss the opportunity to learn how our HCAb technology can transform your biotherapeutic development. Also, make sure to catch Dr. Jiyong Zhang, Nona’s Chief Business Officer, as he shares the latest innovations in immunotherapy using our HCAb platform. It’s a session you won’t want to miss! Learn more about our HCAb Harbour Mice? platform: https://lnkd.in/dfgdKMeH #FestivalofBiologics #FOB #FOB2024 #HCAb #antibodies #biotherapeutics #Biotech #fullyhuman #CART #ADC #multispecific #bispecific #immunotherapy #Tcellengager #TCE

We're pleased to announce Nona Biosciences' strategic collaboration with OverT Bio! By leveraging Nona's fully human HCAb Harbour Mice? platform and the NonaCarFx? platform, along with OverT Bio's innovative approaches, we aim to advance next-generation cell therapies for solid tumors. The fully human heavy chain-only antibodies (HCAbs) generated from Nona's HCAb Harbour Mice? platform offer an ideal modality for CAR-based cell therapies. Unlike traditional methods, these HCAbs have the potential to significantly reduce immunogenicity. Their compact size, simplified structure, and precisely calibrated binding properties provide enhanced versatility in CAR design. With these advantages, we're poised to drive the future of cell therapy and offer new hope to patients battling solid tumors. Stay tuned for more updates on this exciting partnership! Learn more: https://lnkd.in/geCKdqpA #NonaBiosciences #HarbourMice #CART #oncology

Big News in Science! Congratulations to Victor Ambros and Gary Ruvkun, the winners of the 2024 Nobel Prize in Physiology or Medicine. Their groundbreaking discovery of microRNA has revolutionized our understanding of gene regulation. By uncovering how microRNA controls gene expression after transcription, they’ve opened new avenues for research and therapies targeting diseases such as cancer?and autoimmune diseases. At Nona Biosciences, we’re at the forefront of therapeutic innovation. Our services focus on the discovery and development of fully human antibodies that are hyper-targeted, ensuring precise therapeutic interventions for a range of diseases. Discover more: https://lnkd.in/dfgdKMeH #NobelPrize #Science #Medicine #microRNA #GeneRegulation #Biotech #Antibodydiscovery #TargetedTherapies #fullyhuman #antibodies

CD3-based bispecific antibodies are transforming cancer treatment and showing promise for autoimmune diseases. Nona Biosciences’ HBICE? platform leverages Heavy Chain Only Antibodies (HCAbs) to enhance tumor targeting and immune cell activation. Explore how the HBICE? platform optimizes T Cell Engager (TCE) cytotoxicity while minimizing risks like cytokine release syndrome (CRS). Key Learning Objectives: ? Understand TCEs' role in cancer therapy ? Dive into the MOA of CD3 TCEs ? Discover the potential of CD3 HBICE? for solid tumors with fewer adverse events ?? Learn more: https://lnkd.in/eFBC6Mid #Immunotherapy #CancerTreatment #Biotechnology #TCellEngagers #NonaBiosciences #HBICE #Oncology #AutoimmuneTherapy

Will you be attending the Festival of Biologics in Basel from October 15-17? We’re excited to announce that Nona is a Diamond Sponsor this year! Visit us at Booth #736 to learn how our HCAb technology can elevate your biotherapeutic development. Dr. Jiyong Zhang, Nona’s Chief Business Officer, will be presenting on the latest advancements and insights in immunotherapy using our HCAb platform. Be sure to mark your calendar—you won’t want to miss this session! Discover about HCAb Harbour Mice? platform: https://lnkd.in/dfgdKMeH #FestivalofBiologics #FOB #FOB2024 #HCAb #antibodies #biotherapeutics #Biotech #fullyhuman #CART #ADC #multispecific #bispecific #immunotherapy #Tcellengager #TCE

Explore how the HBICE? platform optimizes TCE cytotoxicity while minimizing adverse events like cytokine release syndrome (CRS) ?? ? Key Learning Objectives: ??Understand the Role of T Cell Engagers (TCEs) in Cancer Therapy ??Explore the Mechanism of Action (MOA) of CD3 TCEs ??Examine the CD3 HBICE? Platform’s Optimization for T Cell Engagement ??Recognize the Therapeutic Potential of CD3 HBICE? in Solid Tumors with Reduced Risk of Adverse Events ? ??Download the white paper here to get more insights: https://lnkd.in/esybdyr3 ? #Immunotherapy #CancerResearch #TCellEngagers #TCE #CD3 #BispecificAntibodies #Biotech #HBICE #Immunotherapy

We're pleased to announce that Nona Biosciences has entered a strategic collaboration with Alkyon Therapeutics, a biotechnology company pioneering precision-targeted therapies, to develop next-generation immunotherapeutics and other targeted therapies. This partnership highlights our commitment to applying cutting-edge technology in innovative ways to drive global inventions of transformative next-generation drugs. By leveraging our Harbour Mice? fully human antibody platform and Alkyon's proprietary platform, we will generate deep insights into the tumor microenvironment, advancing novel treatments for solid tumors. Learn more: https://lnkd.in/gFY-yS5A #NonaBiosciences #HarbourMice #immunotherapy #oncology

Our team had the incredible opportunity to attend the CAR TCR Summit in Boston! We were thrilled to present our HCAb-based CAR discovery platform and engage with top scientists from around the world. Curious about how our platform is generating fully human, highly efficient CAR TCR therapeutic drugs? ?? Visit our website to learn more about this innovative technology and its potential to transform the future of immunotherapy! https://lnkd.in/ePDGfAwn #CARTCR #Immunotherapy #Innovation #CARTcell #CART #HCAb #antibodies #Therapeutics #Biotech

Nona Biosciences is attending the CAR-TCR Summit in Boston, MA, from September 17-20. Visit us at Booth #64 to explore our latest innovations in CAR-T technology and learn more about our HCAb platform! Our dedicated scientific team will be on-site to answer all your questions and provide insights into how our fully human heavy chain only antibodies are shaping the future of biotherapeutics. Hope to see you there! Learn more about our HCAb based CAR discovery platform: https://lnkd.in/ePDGfAwn #CARTCR #CARTCRsummit #CARTCR2024 #CART #Immunotherapy #CellTherapy #NextGenBiotherapeutics #Innovation #Biotech #BostonSummit #Oncology